Evaluation of thiol/disulfide homeostasis in patients with a first episode of major depressive disorder

Abstract

Objective: The aim of this study was to investigate the role of dynamic thiol-disulfide homeostasis as a new oxidative stress parameter in patients with major depressive disorder (MDD). Material and Methods: Sixty-three patients with their first episode of untreated MDD, and 61 healthy volunteers were included in the study. Serum thiol/disulfide levels were measured in fasting blood samples. The data were compared between the two groups. Results: No significant difference was observed between the two groups in terms of age, gender distribution, or body mass index. Plasma native and total thiol levels were lower in the MDD group compared to those in the controls (p=0.004, p=0.001). No significant differences were observed between the groups in terms of disulfide, the disulfide/native thiol, the disulfide/total thiol or the native thiol/total thiol ratio (p>0.05). No relationship was detected between these parameters. Conclusion: As far as we know, this is the first study to evaluate changes in thiol/disulfide homeostasis in male and female patients with MDD. Our data show that thiol levels decrease during the first episode of untreated depression. Thiol/disulfide homeostasis may be useful as a biomarker for depression after long-term follow-up and treatment studies.

Keywords

• major depressive disorder,oxidative stress,thiol/disulfide homeostasis

References

1. 1. Gold PW, Machado-Vieira R, Pavlatou MG. Clinical and biochemical manifestations of depression: relation to the neurobiology of stress. Neural plasticity. 2015;2015:581976.
2. 2. Organization WH. The World Health Report 2001: Mental health: new understanding, new hope: World Health Organization; 2001.
3. 3. Michaud CM, Murray CJ, Bloom BR. Burden of disease--implications for future research. Jama. 2001;285:535-9.
4. 4. Aydemir Ö, Ergün H, Soygür H, Kesebir S, Tulunay C. Quality of Life in Major Depressive Disorder: A Cross - Sectional Study. Turkish Journal of Psychiatry. 2009;20:205-12.
5. 5. Chirita AL, Gheorman V, Bondari D, Rogoveanu I. Current understanding of the neurobiology of major depressive disorder. Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie. 2015;56(2Suppl):651-8.
6. 6. Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O. Oxidative stress and antioxidant defense. The World Allergy Organization Journal. 2012;5:9-19.
7. 7. Palta P, Samuel LJ, Miller ER, 3rd, Szanton SL. Depression and oxidative stress: results from a meta-analysis of observational studies. Psychosomatic Med. 2014;76:12-9.
8. 8. Michel TM, Camara S, Tatschner T, Frangou S, Sheldrick AJ, Riederer P, et al. Increased xanthine oxidase in the thalamus and putamen in depression. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. 2010;11:314-20.

9. 9. Cumurcu BE, Ozyurt H, Etikan I, Demir S, Karlidag R. Total antioxidant capacity and total oxidant status in patients with major depression: impact of antidepressant treatment. Psychiatry and Clinical Neurosciences. 2009;63:639-45.
10. 10. Atmaca G. Antioxidant effects of sulfur-containing amino acids. Yonsei Medical Journal. 2004;45:776-88.
11. 11. Dogru A, Balkarli A, Cetin GY, Neselioglu S, Erel O, Tunc SE, et al. Thiol/disulfide homeostasis in patients with ankylosing spondylitis. Bosnian Journal of Basic Medical Sciences. 2016;16:187-92.
12. 12. Avcil S, Uysal P, Avcil M, Alisik M, Bicer C. Dynamic thiol/disulfide homeostasis in children with attention deficit hyperactivity disorder and its relation with disease subtypes. Comprehensive Psychiatry. 2017;73:53-60.
13. 13. Turell L, Radi R, Alvarez B. The thiol pool in human plasma: the central contribution of albumin to redox processes. Free Radical Biology & Medicine. 2013;65:244-53.
14. 14. Matteucci E, Giampietro O. Thiol signalling network with an eye to diabetes. Molecules (Basel, Switzerland). 2010;15:8890-3.
15. 15. Prabhu A, Sarcar B, Kahali S, Yuan Z, Johnson JJ, Adam KP, et al. Cysteine catabolism: a novel metabolic pathway contributing to glioblastoma growth. Cancer Research. 2014;74:787-96.
16. 16. Smeyne M, Smeyne RJ. Glutathione metabolism and Parkinson's disease. Free Radical Biology & Medicine. 2013;62:13-5.
17. 17. Go YM, Jones DP. Cysteine/cystine redox signaling in cardiovascular disease. Free Radical Biology & Medicine. 2011;50:495-509.
18. 18. Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochemistry and Function. 2002;20:171-5.
19. 19. Ranjekar PK, Hinge A, Hegde MV, Ghate M, Kale A, Sitasawad S, et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Research. 2003;121:109-22.
20. 20. Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. The International Journal of Neuropsychopharmacology. 2008;11:851-76.
21. 21. Görmez V, Örengül AC, Özer ÖF, Uzuner S, Selek Ş. Thiol/Disulphide Homeostasis and Oxidative Stress Parameters in Children and Adolescents with Attention Deficit/Hyperactivity Disorder. Anatolian Clinic the Journal of Medical Sciences. 2016;21:179-86.
22. 22. Topcuoglu C, Bakirhan A, Yilmaz FM, Neselioglu S, Erel O, Sahiner SY. Thiol/disulfide homeostasis in untreated schizophrenia patients. Psychiatry Research. 2017;251:212-16.
23. 23. Asoğlu M, Kiliçaslan F, Beginoğlu Ö, Fedai Ü, Akil Ö, Çelik H, et al. Thiol/disulphide homeostasis as a new oxidative stress marker in untreated patients with generalized anxiety disorder. Anatolian Journal of Psychiatry. 2018;19:143-9.
24. 24. Baykan H, Durmaz O, Baykan Ö, Alişik M, Şahin M.C, Karlıdere T, et al. Dynamic thiol/disulphide homeostasis as a novel oxidative stress marker in women with major depressive disorder. Anatolian Jounal of Psychiatry. 2018;19:135-42.
25. 25. Erzin G, Kotan VO, Topcuoglu C, Ozkaya G, Erel O, Yuksel RN, et al. Thiol/disulphide homeostasis in bipolar disorder. Psychiatry Research. 2018;261:237-42.
26. 26. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry. 1960;23:56-62.
27. 27. Akdemir A, Turkcapar MH, Orsel SD, Demirergi N, Dag I, Ozbay MH. Reliability and validity of the Turkish version of the Hamilton Depression Rating Scale. Comprehensive Psychiatry. 2001;42:161-5.
28. 28. Erel O, Neselioglu S. A novel and automated assay for thiol/disulphide homeostasis. Clinical Biochemistry. 2014;47:326-32.
29. 29. Jimenez-Fernandez S, Gurpegui M, Diaz-Atienza F, Perez-Costillas L, Gerstenberg M, Correll CU. Oxidative stress and antioxidant parameters in patients with major depressive disorder compared to healthy controls before and after antidepressant treatment: results from a meta-analysis. The Journal of Clinical Psychiatry. 2015;76:1658-67.
30. 30. Jones DP, Liang Y. Measuring the poise of thiol/disulfide couples in vivo. Free Radical Biology & Medicine. 2009;47:1329-38.
31. 31. Sen CK, Packer L. Thiol homeostasis and supplements in physical exercise. The American Journal of Clinical Nutrition. 2000;72(2 Suppl):653-69.
32. 32. Vural G, Gumusyayla S, Bektas H, Deniz O, Alisik M, Erel O. Impairment of dynamic thiol-disulphide homeostasis in patients with idiopathic Parkinson's disease and its relationship with clinical stage of disease. Clinical Neurology and Neurosurgery. 2017;153:50-5.
33. 33. Andreazza AC, Kauer-Sant'anna M, Frey BN, Bond DJ, Kapczinski F, Young LT, et al. Oxidative stress markers in bipolar disorder: a meta-analysis. Journal of Affective Disorders. 2008;111:135-44.
34. 34. Bouayed J, Rammal H, Soulimani R. Oxidative stress and anxiety: relationship and cellular pathways. Oxidative Medicine and Cellular Longevity. 2009;2:63-7.
35. 35. Genc A, Kalelioglu T, Karamustafalioglu N, Tasdemir A, Gungor FC, Genc ES, et al. Level of plasma thioredoxin in male patients with manic episode at initial and post-electroconvulsive or antipsychotic treatment. Psychiatry and Clinical Neurosciences. 2015;69:344-50.
36. 36. Bitanihirwe BK, Woo TU. Oxidative stress in schizophrenia: an integrated approach. Neuroscience and Biobehavioral Reviews. 2011;35:878-93.
37. 37. Emhan A, Selek S, Bayazit H, Fatih Karababa I, Kati M, Aksoy N. Evaluation of oxidative and antioxidative parameters in generalized anxiety disorder. Psychiatry Research. 2015;230:806-10.
38. 38. Herken H, Akyol O, Yilmaz HR, Tutkun H, Savas HA, Ozen ME, et al. Nitric oxide, adenosine deaminase, xanthine oxidase and superoxide dismutase in patients with panic disorder: alterations by antidepressant treatment. Human Psychopharmacology. 2006;21:53-9.
39. 39. Smaga I, Niedzielska E, Gawlik M, Moniczewski A, Krzek J, Przegalinski E, et al. Oxidative stress as an etiological factor and a potential treatment target of psychiatric disorders. Part 2. Depression, anxiety, schizophrenia and autism. Pharmacological Reports : PR. 2015;67:569-80.
40. 40. Kuloglu M, Atmaca M, Tezcan E, Ustundag B, Bulut S. Antioxidant enzyme and malondialdehyde levels in patients with panic disorder. Neuropsychobiology. 2002;46:186-9.